title: [Immunotherapy: an emerging strategies against prostate castration resistant cancer].
abstract: Castration resistant prostate cancer occurs when patients experience disease progression despite appropriate hormonal manipulations. In these patients, chemotherapy remains standard treatment. Preclinical and clinical data have demonstrated the potential utility of an immunotherapy-based approach for the treatment of prostate cancer (PC). The phase III trial (IMPACT) has recently reported an advantage for Sipuleucel-T over placebo, with an overall survival 4.1 months superior to placebo. Sipuleucel-T is also the first FDA-approved immunotherapy for prostate cancer. These promising results need to be confirmed with other large studies and within previous step of PC. Neoplasic cells can escape immune responses by multiple mechanisms. A better knowledge of these mechanisms is of major concern for the future development of new immunotherapies approach.
authors.affiliation: CHU Jean-Minjoz, oncologie médicale, boulevard Flemming, 25000 Besançon, France.
authors.forename: Laura
authors.initials: L
authors.lastname: Mansi
authors.forename: Antoine
authors.initials: A
authors.lastname: Thiery-Vuillemin
authors.forename: Elsa
authors.initials: E
authors.lastname: Kalbacher
authors.forename: Thierry
authors.initials: T
authors.lastname: Nguyen
authors.forename: Tristan
authors.initials: T
authors.lastname: Maurina
authors.forename: Jérémie
authors.initials: J
authors.lastname: Nallet
authors.forename: Stefano
authors.initials: S
authors.lastname: Kim
authors.forename: Christophe
authors.initials: C
authors.lastname: Borg
authors.forename: François
authors.initials: F
authors.lastname: Kleinclauss
authors.forename: Xavier
authors.initials: X
authors.lastname: Pivot
authors.forename: Olivier
authors.initials: O
authors.lastname: Adotevi
mesh_terms: D059250:Administration, Metronomic; D019496:Cancer Vaccines / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000628:therapy*; D014020:Tissue Extracts / Q000627:therapeutic use
chemical_list: D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T